19F NMR monitoring of in vivo tumor metabolism after biochemical modulation of 5-fluorouracil by the uridine phosphorylase inhibitor 5- benzylacyclouridine

Magnetic Resonance in Medicine

Volumn 38, Issue 6, 1997, Pages 907-916

  Holland, Scott K ^a   Bergman, Andries M ^b   Zhao, Yiming ^b   Adams, Earle R ^b   Pizzorno, Giuseppe ^b  

^a UNIVERSITY OF CINCINNATI   (United States)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

5 benzylacyclouridine; 5 fluorouracil; Tumor metabolism monitoring

Indexed keywords

AMINO ACIDS; HISTOLOGY; MAMMALS; METABOLISM; METABOLITES; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PHOSPHORYLATION;

5-BENZYLACYCLOURIDINE; 5-FLUOROURACIL; 5-FLUOROURACIL (5-FU); ANTI-TUMOR ACTIVITIES; ANTINEOPLASTIC EFFECT; BIOCHEMICAL MODULATIONS; CHEMOTHERAPEUTIC TREATMENTS; TUMOR METABOLISMS;

TUMORS;

5 BENZYLACYCLOURIDINE; ENZYME INHIBITOR; FLUORINE; FLUOROPYRIMIDINE DERIVATIVE; FLUOROURACIL; FLUOROURIDINE; UNCLASSIFIED DRUG; URIDINE PHOSPHORYLASE INHIBITOR; 5-BENZYLACYCLOURIDINE; DIAGNOSTIC AGENT; DRUG DERIVATIVE; URACIL; URIDINE PHOSPHORYLASE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; COLON TUMOR; CONTROLLED STUDY; DOSE RESPONSE; DRUG METABOLISM; IN VITRO STUDY; IN VIVO STUDY; INTRAPERITONEAL DRUG ADMINISTRATION; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; ANIMAL; C57BL MOUSE; DRUG ANTAGONISM; EXPERIMENTAL NEOPLASM; METABOLISM;

ANIMALS; COLONIC NEOPLASMS; ENZYME INHIBITORS; FLUORINE RADIOISOTOPES; FLUOROURACIL; MAGNETIC RESONANCE SPECTROSCOPY; MICE; MICE, INBRED C57BL; NEOPLASMS, EXPERIMENTAL; URACIL; URIDINE PHOSPHORYLASE;

EID: 0030608756     PISSN: 07403194     EISSN: None     Source Type: Journal    
DOI: 10.1002/mrm.1910380609     Document Type: Article

References (37)

1. G. Pizzorno, Y. C. Cheng, R. E. Handschumacher, Pyrimidine and purine antimetabolites, in "Cancer Medicine" (J. F. Holland, R. C. Bast, D. L. Morton, E. Frei III, D. W. Kufe, R.R. Weichselbaum, Eds.), 4th ed., pp. 923-948, Williams & Wilkins, Baltimore, 1997.
2. D. S. Martin, Biochemical modulation: perspectives and objectives, in "New Avenues in Developmental Cancer Chemotherapy," Academic Press, New York, 1987.
3. G. J. Peters, C. J. van Groeningen, Clinical relevance of biochemical modulation of 5-fluorouracil. Ann. Oncol. 2, 469-480 (1991).
4. N. E. Kemeny, T. Ahmed, R. A. Michaelson, Activity of sequential low-dose methotrexate and fluorouracil in advanced colorectal carcinoma: attempt at correlation with tissue and blood levels of phosphoribosylpyrophosphate. J. Clin. Oncol. 2, 311-315 (1984).
5. J. C. Marsh, J. R. Bertino, K. H. Katz, C. A. Davis, H. J. Durivage, L. S. Rome, F. Richards, R. L. Capizzi, L. R. Farber, D. N Pasquale, R. Stuart, A. J. Koletsky, R. Makuch, K. O'Hallaren, The influence of drug interval on the effect of methotrexate and fluorouracil in the treatment of advanced colorectal cancer. J. Clin. Oncol. 9, 371-380 (1990).
6. N. Petrelli, H. O. Douglass. Jr., L. Herrera, D. Russell, D. M. Stablein, H. W. Bruckner, R. J. Mayer, R. Schinella, M. D. Green. F. M. Muggia, A. Megibow, E. S. Greenwald, R. M. Bukowski, J. Harris, B. Levin, E. Gaynor, A. Loutfi, M. H. Kaiser, J. S. Barkin, P. Benedetto, P. V. Woolley, R. Nauta, D. W. Weaver, L. P. Leichman, The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: a prospective randomizsd phase III trial. J. Clin. Oncol. 7, 1419-1426 (1989).
7. J. H. Doroshow, P. Multhauf, L. Leong, K. Margolin, T. Litchfield, S. Akman, B. Carr, M. Bertrand, D. Goldberg, D. Blayney, O. Odujinrin, R. Delap, J. Shuster, E. Newman, Prospective randomized comparison of fluorouracil versus fluorouracil and high-dose continuous infusion leucovorin calcium for the treatment of advanced measurable colorectal cancer in patients previously unexposed to chemotherapy. J. Clin. Oncol. 8, 491-501 (1990).
8. D. S. Martin, R. L. Stolfi, R. C. Sawyer, S. Spiegelman, E. S. Casper, C. W. Young, Therapeutic utility of utilizing low doses of N-(phosphonoacetyl)-L-aspartic acid in combination with 5-fluorouracil: a murine study with clinical relevance. Cancer Res. 43, 2317-2311 (1983).
9. B, Ardalan, G. Singh, H. Silberman, A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonoacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancers. J. Clin. Oncol. 6, 1053-1058 (1988).
10. P. J. O'Dwyer, A. R. Paul, J. Walczak, L. M. Weiner, S. Litwin, R. L. Comis, Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J. Clin. Oncol. 8, 1497-1503 (1990).
11. G. Pizzorno, R. A. Wiegand, S. K. Lentz, R. E. Handschumacher, Brequinar potentiates 5-fluorouracil antitumor activity in a murine model colon 38 tumor by tissue-specific modulation of uridine nucleotide pools. Cancer Res. 52, 1660-1665 (1992).
12. A. Buzaid, G. Pizzorno, J. C. Marsh, T. S. Ravikumar, J. R. Murren, M. Todd, R. K. Strair, W.-J. Poo, W. N. Hait, Biochemical modulation of 5-fluorouracil with brequinar: results of a phase I-II study. Cancer Chemother. Pharmacol. 36, 373-378 (1995).
13. P. Piedbois, M. Buyse, Y. Rustum, D. Machover, C. Erlichman, R. W. Carlson, F. Valone, R. Labianca, J. H. Doroshow, N. Petrelli, Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. J. Clin. Oncol. 10, 896-903 (1992).
14. D. Heggie, J.-P. Sommadossi, D. S. Cross, W. J. Huster, R. Diasio, Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine and bile. Cancer Res. 47, 2203-2206 (1987).
15. D. J. T. Porter, W. G. Chestnut, B. M. Merrill, T. Spector, Mechanismbased inactivation of dihydropyrimidine dehydrogenase by 5-ethynyluracil. J. Biol. Chem. 267, 5236-5242 (1992).
16. S. Cao, Y. M. Rustum, T. Spector, 5-Ethynyluracil (776C85): modulation of 5-fluorouracil efficacy and therapeutic index in rats bearing colorectal carcinoma. Cancer Res. 54, 1507-1510 (1994).
17. J. G. Niedzwicki, S. H. Chu, M. H. el Kouni, E. C. Rowe, S, Cha, 5-Benzylacyclouridine and 5-benzyloxybenzylacyclouridine, potent inhibitors of uridine phosphorylase. Biochem. Pharmacol. 31, 1857-1861 (1982).
18. J. W. Darnowski, R. E. Handschumacher, Tissue specific enhancement of uridine utilization and 5-fluorouracil therapy in mice by benzylacyclouridine. Cancer Res. 45, 5364-5368 (1985).
19. D. S. Martin, R.L Stolfi, R. C. Sawyer, Use of oral uridine as a substitute for parenteral uridine rescue of 5-fluorouracil therapy, with and without the uridine phosphorylase inhibitor 5-benzylacyclouridine. Cancer Chemother. Pharmacol. 24, 9-14 (1989).
20. A. Monks, O. Ayers. R. L. Cysyk, Effect of 5-benzylacyclouridine, a potent inhibitor of uridine phosphorylase, on the metabolism of circulating uridine by the isolated rat liver. Biochem. Pharmacol. 32, 2003-2009 (1983).
21. P. E. Sijens, Y. M. Huang, N. J. Baldwin, T. C. Ng, F magnetic resonance spectroscopy studies of the metabolism of 5-fluorouracil in murine RIF-1 tumors and liver. Cancer Res. 51, 1384-1390 (1991).
22. A. El-Tahtawy, W. Wolf, In vivo measurements of intratumoral metabolism, modulation, and pharmacokinetics of 5-fluorouracil, using F nuclear magnetic resonance spectroscopy. Cancer Res. 51, 5806-5812 (1991).
23. J. W. Darnowski, R. E. Handschumacher, Tissue uridine pools: evidence in vivo of a concentrative mechanism for uridine uptake. Cancer Res. 46, 3490-3494 (1986).
24. 19F NMR spectroscopy. Magn. Reson. Med. 19, 113-123 (1991).
25. N. Christophidis, G. Mihaly, M. Vadja, W. Louis, Comparison of liquid-and gas-liquid chromatographic assays of 5-fluorouracil in plasma. Clin. Chem. 25, 83-87 (1979).
26. P. M. McSheehy, M. J. Prior, J. R. Griffiths, Prediction of 5-fluorouracil cytotoxicity towards the Walker carcinosarcoma using peak integrals of fluoronucleotides measured by MRS. Br. J. Cancer. 60, 303-309 (1989).
27. P. E. Sijens, N. J. Baldwin, T. C. Ng, Multinuclear MR investigation of the metabolic response of the murine RIF-1 tumor to 5-fluorouracil chemotherapy Magn. Reson. Med. 19, 373-385 (1991).
28. P. M. J. McSheehy, M. J. W. Prior, J.R Griffiths, Enhanced 5-fluorouracil cytotoxicity and elevated 5-fluoronucleotides in the rat Walker carcinosarcoma following methotrexate pre-treatment: a 19F-MRS study in vivo. Br. J. Cancer 65, 369-375 (1992).
29. 19F magnetic resonance spectroscopy in patients with colorectal cancer: a pilot study. Ann. Oncol. 4, 597-602 (1993).
30. J. W. Darnowski, R. E. Handschumacher, Benzylacyclouridine pharmacokinetics, metabolism and biochemical effect in mice. Biochem. Pharmacol. 37, 2613-2819 (1988).
31. F. N. M. Naguib, M. H. el Kouni, S. M. Cha, Structure-activity relationship of ligands of dihydrouracil dehydrogenase from mouse liver. Biochem. Pharmacol. 38, 1471-1480 (1989).
32. R. K. Jain, Determinants of tumor blood flow: a review. Cancer Res. 48, 2641-2658 (1988).
33. R.K Jain, Physiological resistance to the treatment of solid tumors, in "Drug Resistance in Oncology" (B. A. Teicher, Ed.), pp. 87-105, M. Dekker, New York, 1993.
34. R. K. Jain, Transport of molecules across tumor vasculature. Cancer Metastasis Rev. 6, 559-593 (1987).
35. 19F nuclear magnetic resonance spectroscopy pharmacokinetics. J. Clin. Oncol. 8, 1868-1873 (1990).
36. 19F NMR spectroscopic pharmacokinetics in tumor-bearing humans and rabbits. Proc. Natl. Acad. Sci. USA 87, 492-496 (1990).
37. G. Pizzorno, J. C. Marsh, J. J. Leffert, R. E. Handschumacher, P. Calabresi, Pharmacokinetics of benzylacyclouridine (BAU) in patients with refractory solid tumors (phase I trial). Proc. Am. Assoc. Cancer Res. 34, 22 (1993).